Michael Rape

Michael Rape has extensive work experience in various roles within the biotechnology and academia sectors. Michael is currently a Co-Founder of Lyterian Therapeutics, a position they have held since November 2022. Michael also serves as a Member of the Scientific Advisory Board for Vicinitas Therapeutics, starting in July 2022. Prior to their current roles, Michael was the Head of the Division of Molecular Therapeutics and a Professor at the University of California, Berkeley, starting in July 2006. Michael also held the position of iPartner at The Column Group from January 2021. Additionally, they were an Investigator at the Howard Hughes Medical Institute starting in September 2013. Michael has also served in advisory roles for Monte Rosa Therapeutics and Nurix, Inc. Overall, their work experience demonstrates a strong expertise in molecular therapeutics and biotechnology.

Michael Rape pursued a PhD in yeast genetics from 1999 to 2002 at the Max Planck Institute of Biochemistry in Germany.